Nasdaq
$58.02▼ 0.01%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $8.17BShares out 1.400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 8.20After-hours26.08.21 06:254Ownership#●●●#●●●
ARROWHEAD PHARMACEUTICALS, INC.
Adeoye Y. Olukotun, an insider at Arrowhead Pharmaceuticals, filed an SEC Form 4 on August 20, 2026, reporting a change in beneficial ownership of securities as of August 18, 2026. Investors should review the filing to identify the specific nature of the insider's transaction.…more
$58.02-0.01%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.20After-hours26.08.21 06:224Ownership
ARROWHEAD PHARMACEUTICALS, INC.
Michael S. Perry, a director at Arrowhead Pharmaceuticals, filed an SEC Form 4 on August 20, 2026, regarding a change in beneficial ownership of securities effective August 18, 2026. This filing serves as an official disclosure of the insider's updated stock holdings.…more
$58.02-0.01%vs prev closeView filingShare - 8.18After-hours26.08.19 06:31144Ownership
ARROWHEAD PHARMACEUTICALS, INC.
Olukotun Adeoye Y, an insider at Arrowhead Pharmaceuticals (ARWR), has filed a Form 144 regarding the proposed sale of company securities. This filing serves as an official notification of the insider's intent to sell shares in the open market.…more
$58.02-0.01%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14Regular26.10.15 02:05#●●●#●●●#●●●
Arrowhead Pharmaceuticals Reports Promising Early Clinical Data for Alzheimer's Drug ARO-MAPT…more
Arrowhead Pharmaceuticals announced that its investigational Alzheimer's therapy, ARO-MAPT, successfully reduced tau protein levels by up to 85% in early clinical trials. While the results validate the company's drug delivery platform and safety profile, further data on cognitive improvement in patients is required.…more
$58.02-0.01%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.14Pre-market26.10.14 20:32
●●●●●●●● ●●●●● ●●●●●●
Arrowhead's ARO-MAPT demonstrated a significant reduction in cerebrospinal fluid tau protein, validating its platform's ability to cross the blood-brain barrier. While these early results support potential quarterly dosing, further clinical trials are required to confirm therapeutic efficacy.…more
$58.02-0.01%vs prev closeShareBenzinga - 9.16Pre-market26.09.16 20:39
●●●●●●●● ●●●●● ●●●●●●
Arrowhead Pharmaceuticals announced positive interim Phase 1/2a clinical data for its ARO-DIMER-PA candidate, demonstrating significant reductions in key lipids. The results validate the company's RNAi platform and strengthen its strategic focus on cardiometabolic diseases.…more
$58.02-0.01%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report